Huwel Lifesciences

Hemomeasure & UniAmp - Point-of-Care Diagnostic Devices

CURRENT IMPACT

As on March 2024

24

UniAmp devices deployed across
Karnataka, Madhya Pradesh, and Uttar Pradesh

Geographical Focus
  • Pan-India
Potential Impact
  • Deploy

    500


    Uniamp and 1000 Hemomeasure devices in private healthcare facilities across India.

Samridh support

SAMRIDH’s financial support through the Recoverable Grant tool will cover Huwel Lifesciences’ operational expenses for eight months. This support aims
to scale up and deploy its Uniamp and Hemomeasure devices across various private and public healthcare facilities throughout India. The financial assistance will also be allocated to conducting training sessions, integrating technologies, and expanding existing device manufacturing facilities. These efforts are intended to enhance accessibility, reduce development costs, and ultimately benefit healthcare facilities utilizing the devices while contributing
to job creation. SAMRIDH’s support is expected to provide an additional leverage of ~4.6 times, with Huwel targeting a raise of INR 11.5 Cr in the current financial year.

~70% of medical decisions rely on lab results[1]

70% of Indians lack access to essential healthcare services, including diagnostic facilities. [2]

~10 – 15% of healthcare expenditure in India is attributed to diagnostic tests [3]

~80% of India’s medical devices are imported from foreign suppliers, typically comprising diagnostic equipment[4]

In Rural India, the lack of access to affordable and quality diagnostic facilities, presents a pressing challenge to the existing healthcare ecosystem. This gap limits early detection and treatment of infectious diseases like tuberculosis, influenza, and COVID-19, worsening their burden on individuals and the healthcare system. Compounding this issue is India’s dependence on imported medical devices, escalating the cost of diagnostics. This is reflective in the high out-of-pocket expenditure on healthcare. To address this crisis, bolstering domestic manufacturing capabilities of affordable, new-age diagnostic tools is essential to promote early detection, timely treatment, and better health outcomes for all Indians.

[1] NATHEALTH HEALTHCARE FEDERATION OF INDIA. n.d. “ An assessment of India’s laboratory diagnostic industry a strategic pillar of healthcare : Opportunities ahead: .” Https://aspirecircle.org/. NATHEALTH. Consulté le March 28, 2024. Accessed March 28, 2024.

[2] Rangaranjan, Radha. 2021. “ Addressing the gap in diagnostic services in rural India .” ETHealthworld.com, July 15, 2021.

[3] Kumawat, Pritam. 2024. “ Bridging healthcare gaps: The impact of Point-of-Care diagnostics in India ” ETHealthworld.com, February 22, 2024.

[4] The Legal 500. 2023. “ Import of Medical Devices into India: Opportunities and Challenges – Legal Developments. ” The Legal 500. September 11, 2023.

Huwel Lifesciences specializes in manufacturing molecular diagnostic kits, including PCR, Real-Time PCR, LAMP kits, enzymes, and extraction kits. SAMRIDH supports Huwel’s two point-of-care (POCT) diagnostic devices: Hemomeasure and UniAmp. Hemomeasure, a palm-top device, provides quick haemoglobin measurement in just two minutes with just 4 µl of blood, enhancing accessibility to ferritin and Vitamin D tests. UniAmp, a molecular POCT device capable of detecting various infectious diseases, including Tuberculosis, Influenza, and COVID-19, without requiring a controlled environment, delivers results onsite within 7-35 minutes. Rapid card tests for Serum Ferritin and Vitamin D levels have also been developed to address the rise in lifestyle diseases in India, offering accuracy, user-friendliness, and cost-effectiveness.

s